Formulations and Characterization of Liquid SMEDDS of Dexlansoprazole

Abstract

Dexlansoprazole is a second-generation proton pump inhibitor (PPI) used in the treatment of
symptoms of gastroesophageal reflux disease (GERD) and erosive esophagitis (esophageal damage caused by acid in stomach), but because of poor solubility, stability and oral bioavailability. The objective of our research was to formulate a self-micro emulsifying drug delivery system (SMEDDS) of Dexlansorazole by minimum surfactant concentration which would improve its solubility, stability and oral bioavailability. Optimized formula [C7IIB] composition includes Capryol 90 as oil, Labrasol as surfactant and Captex 500 as cosurfactant containing 30 mg of Dexlansoprazole showing drug release for liquid SMEDDS formulation (99.9%), droplet size (9.10 nm), Zeta potential (-23.9), viscosity (0.9141 cP) and infinite dilution capacity. In-vitro drug release of C7IIB was extremely high (p <0.05) compared with marketed conventional capsules (M). C7IIB was also employed to develop various SMEDDS formulations (Powder-filled capsule).